Wenxin Zhang

Zonghao Ying, Guangyi Zheng, Yongxin Huang et al.

This study presents the first comprehensive safety evaluation of the DeepSeek models, focusing on evaluating the safety risks associated with their generated content. Our evaluation encompasses DeepSeek's latest generation of large language models, multimodal large language models, and text-to-image models, systematically examining their performance regarding unsafe content generation. Notably, we developed a bilingual (Chinese-English) safety evaluation dataset tailored to Chinese sociocultural contexts, enabling a more thorough evaluation of the safety capabilities of Chinese-developed models. Experimental results indicate that despite their strong general capabilities, DeepSeek models exhibit significant safety vulnerabilities across multiple risk dimensions, including algorithmic discrimination and sexual content. These findings provide crucial insights for understanding and improving the safety of large foundation models. Our code is available at https://github.com/NY1024/DeepSeek-Safety-Eval.

Michael Nercessian, Wenxin Zhang, Alexander Schubert et al.

Randomized controlled trials (RCTs) are indispensable for establishing the clinical value of medical artificial-intelligence (AI) tools, yet their high cost and long timelines hinder timely validation as new models emerge rapidly. Here, we propose BRIDGE, a data-reuse RCT design for AI-based risk models. AI risk models support a broad range of interventions, including screening, treatment selection, and clinical alerts. BRIDGE trials recycle participant-level data from completed trials of AI models when legacy and updated models make concordant predictions, thereby reducing the enrollment requirement for subsequent trials. We provide a practical checklist for investigators to assess whether reusing data from previous trials allows for valid causal inference and preserves type I error. Using real-world datasets across breast cancer, cardiovascular disease, and sepsis, we demonstrate concordance between successive AI models, with up to 64.8% overlap in top 5% high-risk cohorts. We then simulate a series of breast cancer screening studies, where our design reduced required enrollment by 46.6%--saving over US$2.8 million--while maintaining 80% power. By transforming trials into adaptive, modular studies, our proposed design makes Level I evidence generation feasible for every model iteration, thereby accelerating cost-effective translation of AI into routine care.